Phase III Vitiligo Study]

计划入组 200 人

Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zoster in Vulnerable Population Receiving ImmunOmodulaNt Therapies

计划入组 150 人 · 首次发布于 2026 年 4 月 16 日

Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls

计划入组 225 人 · 首次发布于 2022 年 10 月 12 日

X-Synergy®

NanoLithium® NP03

Integra®-SC

GENOMIC HEALTH, INC.

United States

Clinuvel Pharmaceuticals Ltd

Australia

Theralase Technologies Inc

Canada

SCENESSE® (Afamelanotide) Approved by Health Canada for Erythropoietic Protoporphyria

CLINUVEL Seeks Canadian Approval for SCENESSE® in Erythropoietic Protoporphyria

Clinuvel Advances Phase III Trial for Vitiligo Treatment with SCENESSE®, Recruiting Over 200 Patients